CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Core Insights - Cumberland Pharmaceuticals Inc. reported combined net revenues of $8.3 million for Q3 2025, with year-to-date revenues reaching $30.8 million, a 12% increase compared to the same period in 2024 [1][17][18] Financial Performance - Total operating expenses for Q3 2025 were $10.3 million, leading to a net loss of approximately $1.9 million for the quarter and a year-to-date net loss of about $1.4 million [18][19] - The company ended Q3 2025 with total assets of approximately $66 million, liabilities of $40 million, and shareholders' equity of $26 million [2][19] Product Portfolio and Developments - Cumberland added Talicia, an FDA-approved product for treating H. pylori infection, to its commercial portfolio through a partnership with RedHill Biopharma [4][5] - The company has formed Talicia Holdings, Inc., with RedHill holding a 70% ownership stake, while Cumberland invests $4 million over two years for a 30% stake [5][6] - Talicia is now recommended as a first-line therapy in clinical guidelines and is patent protected until 2042 [7] International Expansion - Cumberland launched Vibativ in Saudi Arabia through an agreement with Tabuk Pharmaceutical, which has exclusive distribution rights in Saudi Arabia and Jordan [8][9] - The company also received regulatory approval for its ibuprofen injection product in Mexico and Vibativ in China [9] Clinical Trials and Research - Cumberland's ifetroban product candidate showed a 5.4% improvement in cardiac function in a Phase II trial for Duchenne muscular dystrophy [13][14] - The company is also conducting Phase II trials for ifetroban in systemic sclerosis and idiopathic pulmonary fibrosis [15][16]